The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry : clues for the optimization of rituximab treatment strategies.

Vander Cruyssen, Bert;Durez, Patrick;Westhovens, Rene;Kaiser, Marie-Joelle;De Keyser, Filip;et.al.
(2010) Arthritis Research & Therapy —

Files

ar3129.pdf
  • Open Access
  • Adobe PDF
  • 520.56 KB
Download

Details

Authors
  • Vander Cruyssen, Bert
    Author
  • Durez, PatrickUCLouvain
    Author
  • Westhovens, Rene
    Author
  • Kaiser, Marie-Joelle
    Author
  • De Keyser, Filip
    Author
Show more
Abstract
This study describes the results of the Belgian 'MabThera In Rheumatoid Arthritis (MIRA)' registry: effectiveness, safety and evaluation of the current retreatment practice on the background of the Belgian reimbursement criteria for rituximab.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Vander Cruyssen, B., Durez, P., Westhovens, R., Kaiser, M.-J., Hoffman, I., & De Keyser, F. (2010). The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry : clues for the optimization of rituximab treatment strategies. Arthritis Research & Therapy. https://doi.org/10.1186/ar3129